{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:26:55Z","timestamp":1762100815454},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.leukres.2008.07.011","type":"journal-article","created":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T12:00:43Z","timestamp":1219320043000},"page":"336-339","source":"Crossref","is-referenced-by-count":7,"title":["Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"33","author":[{"given":"Mariela","family":"Valle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon E.","family":"Plon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5 (December)","key":"10.1016\/j.leukres.2008.07.011_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2006.06337.x","article-title":"Down syndrome and acute lymphoblastic leukaemia","volume":"135","author":"Whitlock","year":"2006","journal-title":"Br J Haematol"},{"issue":"1 (January)","key":"10.1016\/j.leukres.2008.07.011_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pbc.20092","article-title":"Down syndrome, drug metabolism and chromosome 21","volume":"44","author":"Taub","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"1 (January)","key":"10.1016\/j.leukres.2008.07.011_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/pbc.20207","article-title":"Acute myeloid leukemia and Down syndrome evolution of modern therapy-state of the art review","volume":"44","author":"Gamis","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"1\u20132 (December)","key":"10.1016\/j.leukres.2008.07.011_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"issue":"1 (July)","key":"10.1016\/j.leukres.2008.07.011_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9 (May)","key":"10.1016\/j.leukres.2008.07.011_bib6","first-page":"2372","article-title":"WRN or telomerase constructs reverse 4-nitroquinoline 1-oxide sensitivity in transformed Werner syndrome fibroblasts","volume":"60","author":"Hisama","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.07.011_bib7","series-title":"Methods in molecular medicine","first-page":"21","article-title":"Clonogenic cell survival assay","author":"Munshi","year":"2005"},{"issue":"1 (January)","key":"10.1016\/j.leukres.2008.07.011_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood"},{"issue":"5 (May)","key":"10.1016\/j.leukres.2008.07.011_bib9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.leu.2401753","article-title":"Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?","volume":"14","author":"Frost","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.07.011_bib10","first-page":"204","article-title":"Immunology of Down syndrome: a review","volume":"7","author":"Ugazio","year":"1990","journal-title":"Am J Med Genet Suppl"},{"issue":"1 (January)","key":"10.1016\/j.leukres.2008.07.011_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1139\/G07-100","article-title":"Identification of dysregulated genes in lymphocytes from children with Down syndrome","volume":"51","author":"Sommer","year":"2008","journal-title":"Genome"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260800341X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521260800341X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T14:01:57Z","timestamp":1557756117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521260800341X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S014521260800341X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.07.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}